Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119651 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
A Phase 1 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT01119651 is a Phase 1 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 59 participants.
The verdict
NCT01119651, a Phase 1 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.
Interventions
- DRUG Tazarotene (Patch application in Challenge Phase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-06-14 |
| Est. Completion | 2010-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119651
The ClinicalTrials.gov registry entry for NCT01119651 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tazarotene (Patch application in Challenge Phase) is the first listed.
NCT01119651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119651 about?
NCT01119651 is a clinical study titled "A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.". The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.
What is the current status of trial NCT01119651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2010-06-14. Estimated completion is 2010-06-26.
What interventions are being tested in trial NCT01119651?
The interventions under investigation include: Tazarotene (Patch application in Challenge Phase) (DRUG).
Who is sponsoring clinical trial NCT01119651?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.